Aclaris Historical Financial Ratios

ACRS Stock

USD 3.99 0.19 5.00%

Aclaris Therapeutics is presently reporting on over 111 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 0.67 or Days Sales Outstanding of 3.31 will help investors to properly organize and evaluate Aclaris Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aclaris Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.

About Aclaris Financial Ratios Analysis

Aclaris TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Aclaris Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Aclaris financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Aclaris Therapeutics history.

Aclaris Therapeutics Financial Ratios Chart

At this time, Aclaris Therapeutics' PTB Ratio is comparatively stable compared to the past year. PB Ratio is likely to gain to 0.67 in 2024, whereas Days Sales Outstanding is likely to drop 3.31 in 2024.

Price To Sales Ratio Ptb Ratio Days Sales Outstanding Operating Cash Flow Per Share Ev To Sales Asset Turnover

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Aclaris Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Aclaris Therapeutics sales, a figure that is much harder to manipulate than other Aclaris Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Operating Cash Flow Per Share

A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Asset Turnover

The ratio of net sales to average total assets, indicating how efficiently a company uses its assets to generate sales.

Most ratios from Aclaris Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Aclaris Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aclaris Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.At this time, Aclaris Therapeutics' PTB Ratio is comparatively stable compared to the past year. PB Ratio is likely to gain to 0.67 in 2024, whereas Days Sales Outstanding is likely to drop 3.31 in 2024.

	2021	2022	2023	2024 (projected)
Net Debt To EBITDA	0.41	0.53	0.34	0.32
Intangibles To Total Assets	0.0281	0.0274	0.001363	0.001295

Net Debt To E B I T D A Intangibles To Total Assets

Aclaris Therapeutics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio
Price To Sales Ratio		-0.6	0.95	0.04	0.68	0.2	0.7	-0.6	1.0	0.2	0.77	-0.24	0.32	-0.64	-0.79	0.95	0.29	-0.76	-0.46	-0.69	-0.76	0.92	0.54	0.77	-0.73	-0.8
Ptb Ratio	-0.6		-0.57	0.56	-0.26	-0.53	-0.94	1.0	-0.59	-0.53	-0.76	0.08	-0.61	0.2	0.41	-0.63	0.42	0.69	0.13	0.94	0.69	-0.71	-0.64	-0.77	0.68	0.81
Days Sales Outstanding	0.95	-0.57		0.01	0.57	0.12	0.66	-0.57	0.94	0.11	0.58	-0.18	0.21	-0.59	-0.87	0.98	0.26	-0.67	-0.56	-0.67	-0.66	0.88	0.4	0.57	-0.64	-0.72
Book Value Per Share	0.04	0.56	0.01		0.04	-0.84	-0.59	0.56	0.05	-0.84	-0.27	0.2	-0.75	0.03	-0.09	0.03	0.9	0.36	-0.07	0.54	0.36	-0.07	-0.09	-0.25	0.36	0.4
Free Cash Flow Yield	0.68	-0.26	0.57	0.04		0.28	0.45	-0.26	0.71	0.28	0.69	-0.05	0.32	-0.78	-0.66	0.49	0.23	-0.79	-0.68	-0.35	-0.79	0.57	0.25	0.63	-0.79	-0.72
Operating Cash Flow Per Share	0.2	-0.53	0.12	-0.84	0.28		0.6	-0.53	0.21	1.0	0.52	-0.54	0.95	-0.4	0.05	0.08	-0.7	-0.63	0.08	-0.51	-0.63	0.24	0.22	0.49	-0.63	-0.6
Capex To Depreciation	0.7	-0.94	0.66	-0.59	0.45	0.6		-0.94	0.69	0.6	0.83	-0.17	0.69	-0.39	-0.51	0.68	-0.39	-0.77	-0.27	-0.98	-0.77	0.79	0.65	0.82	-0.76	-0.87
Pb Ratio	-0.6	1.0	-0.57	0.56	-0.26	-0.53	-0.94		-0.59	-0.53	-0.76	0.08	-0.61	0.2	0.41	-0.63	0.42	0.69	0.13	0.94	0.69	-0.71	-0.64	-0.77	0.68	0.81
Ev To Sales	1.0	-0.59	0.94	0.05	0.71	0.21	0.69	-0.59		0.21	0.77	-0.24	0.32	-0.67	-0.8	0.94	0.29	-0.78	-0.48	-0.67	-0.77	0.91	0.51	0.77	-0.75	-0.8
Free Cash Flow Per Share	0.2	-0.53	0.11	-0.84	0.28	1.0	0.6	-0.53	0.21		0.52	-0.54	0.95	-0.4	0.05	0.08	-0.7	-0.63	0.08	-0.5	-0.63	0.24	0.22	0.49	-0.63	-0.6
Roic	0.77	-0.76	0.58	-0.27	0.69	0.52	0.83	-0.76	0.77	0.52		-0.16	0.64	-0.54	-0.44	0.62	-0.1	-0.83	-0.2	-0.78	-0.83	0.77	0.71	0.99	-0.82	-0.87
Inventory Turnover	-0.24	0.08	-0.18	0.2	-0.05	-0.54	-0.17	0.08	-0.24	-0.54	-0.16		-0.6	0.36	-0.14	-0.16	0.09	0.29	-0.23	0.16	0.28	-0.19	-0.21	-0.16	0.28	0.26
Net Income Per Share	0.32	-0.61	0.21	-0.75	0.32	0.95	0.69	-0.61	0.32	0.95	0.64	-0.6		-0.43	0.05	0.2	-0.6	-0.64	0.13	-0.63	-0.64	0.38	0.49	0.62	-0.63	-0.67
Days Of Inventory On Hand	-0.64	0.2	-0.59	0.03	-0.78	-0.4	-0.39	0.2	-0.67	-0.4	-0.54	0.36	-0.43		0.52	-0.45	-0.15	0.64	0.42	0.32	0.64	-0.52	-0.19	-0.47	0.63	0.56
Payables Turnover	-0.79	0.41	-0.87	-0.09	-0.66	0.05	-0.51	0.41	-0.8	0.05	-0.44	-0.14	0.05	0.52		-0.81	-0.27	0.65	0.83	0.47	0.64	-0.72	-0.07	-0.41	0.64	0.63
Capex To Revenue	0.95	-0.63	0.98	0.03	0.49	0.08	0.68	-0.63	0.94	0.08	0.62	-0.16	0.2	-0.45	-0.81		0.27	-0.64	-0.46	-0.7	-0.63	0.9	0.5	0.63	-0.61	-0.72
Cash Per Share	0.29	0.42	0.26	0.9	0.23	-0.7	-0.39	0.42	0.29	-0.7	-0.1	0.09	-0.6	-0.15	-0.27	0.27		0.17	-0.21	0.31	0.17	0.05	0.02	-0.08	0.2	0.19
Pocfratio	-0.76	0.69	-0.67	0.36	-0.79	-0.63	-0.77	0.69	-0.78	-0.63	-0.83	0.29	-0.64	0.64	0.65	-0.64	0.17		0.51	0.67	1.0	-0.74	-0.36	-0.8	1.0	0.97
Interest Coverage	-0.46	0.13	-0.56	-0.07	-0.68	0.08	-0.27	0.13	-0.48	0.08	-0.2	-0.23	0.13	0.42	0.83	-0.46	-0.21	0.51		0.21	0.51	-0.4	0.16	-0.15	0.51	0.46
Capex To Operating Cash Flow	-0.69	0.94	-0.67	0.54	-0.35	-0.51	-0.98	0.94	-0.67	-0.5	-0.78	0.16	-0.63	0.32	0.47	-0.7	0.31	0.67	0.21		0.67	-0.75	-0.72	-0.78	0.65	0.81
Pfcf Ratio	-0.76	0.69	-0.66	0.36	-0.79	-0.63	-0.77	0.69	-0.77	-0.63	-0.83	0.28	-0.64	0.64	0.64	-0.63	0.17	1.0	0.51	0.67		-0.73	-0.36	-0.79	1.0	0.97
Days Payables Outstanding	0.92	-0.71	0.88	-0.07	0.57	0.24	0.79	-0.71	0.91	0.24	0.77	-0.19	0.38	-0.52	-0.72	0.9	0.05	-0.74	-0.4	-0.75	-0.73		0.61	0.77	-0.74	-0.81
Income Quality	0.54	-0.64	0.4	-0.09	0.25	0.22	0.65	-0.64	0.51	0.22	0.71	-0.21	0.49	-0.19	-0.07	0.5	0.02	-0.36	0.16	-0.72	-0.36	0.61		0.74	-0.34	-0.54
Roe	0.77	-0.77	0.57	-0.25	0.63	0.49	0.82	-0.77	0.77	0.49	0.99	-0.16	0.62	-0.47	-0.41	0.63	-0.08	-0.8	-0.15	-0.78	-0.79	0.77	0.74		-0.79	-0.84
Ev To Operating Cash Flow	-0.73	0.68	-0.64	0.36	-0.79	-0.63	-0.76	0.68	-0.75	-0.63	-0.82	0.28	-0.63	0.63	0.64	-0.61	0.2	1.0	0.51	0.65	1.0	-0.74	-0.34	-0.79		0.96
Pe Ratio	-0.8	0.81	-0.72	0.4	-0.72	-0.6	-0.87	0.81	-0.8	-0.6	-0.87	0.26	-0.67	0.56	0.63	-0.72	0.19	0.97	0.46	0.81	0.97	-0.81	-0.54	-0.84	0.96

Click cells to compare fundamentals

Aclaris Therapeutics Account Relationship Matchups

Aclaris Therapeutics fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Price To Sales Ratio	18.48	42.46	122.0	34.52	2.35	2.23
Ptb Ratio	1.12	7.31	4.18	5.2	0.47	0.67
Days Sales Outstanding	60.79	43.47	33.63	5.94	3.48	3.31
Book Value Per Share	1.69	0.89	3.48	3.03	2.25	2.14
Free Cash Flow Yield	(1.26)	(0.14)	(0.0636)	(0.0664)	(1.09)	(1.03)
Operating Cash Flow Per Share	(2.33)	(0.91)	(0.92)	(1.04)	(1.12)	(1.18)
Stock Based Compensation To Revenue	3.83	1.73	2.08	0.51	0.66	0.62
Capex To Depreciation	0.25	0.34	0.33	0.76	1.52	1.44
Pb Ratio	1.12	7.31	4.18	5.2	0.47	0.67
Ev To Sales	10.13	35.85	118.06	33.02	1.08	1.03
Free Cash Flow Per Share	(3.1)	(2.37)	(0.92)	(1.05)	(1.14)	(1.2)
Roic	(1.98)	(1.04)	(0.42)	(0.44)	(0.62)	(0.65)
Inventory Turnover	8.66	0.82	(0.14)	(0.98)	(1.12)	(1.07)
Net Income Per Share	(3.46)	(1.2)	(2.01)	(1.36)	(1.27)	(1.33)
Days Of Inventory On Hand	42.15	447.0	(2.7K)	(373.61)	(336.25)	(353.06)
Payables Turnover	0.41	0.98	0.47	1.16	2.04	2.14
Sales General And Administrative To Revenue	6.42	3.17	3.49	0.84	1.0	0.95
Research And Ddevelopement To Revenue	15.35	4.9	6.48	2.62	3.15	2.99
Capex To Revenue	0.38	0.0699	0.0456	0.0203	0.0419	0.0398
Cash Per Share	1.82	2.03	3.37	3.34	1.71	1.62
Pocfratio	(0.81)	(7.12)	(15.82)	(15.2)	(0.94)	(0.98)
Capex To Operating Cash Flow	(0.0135)	(0.0167)	(0.0117)	(0.005908)	(0.008954)	(0.0175)
Pfcf Ratio	(0.8)	(7.04)	(15.73)	(15.07)	(0.92)	(0.97)
Days Payables Outstanding	892.65	373.6	773.29	315.9	179.22	170.26
Roe	(2.04)	(1.36)	(0.58)	(0.45)	(0.56)	(0.59)
Ev To Operating Cash Flow	(0.44)	(6.01)	(15.31)	(14.54)	(0.43)	(0.45)
Pe Ratio	(0.55)	(5.38)	(7.22)	(11.58)	(0.83)	(0.87)
Return On Tangible Assets	(0.72)	(1.57)	(0.8)	(0.47)	(0.36)	(0.45)
Ev To Free Cash Flow	(0.44)	(5.94)	(15.22)	(14.41)	(0.43)	(0.45)
Earnings Yield	(1.83)	(0.19)	(0.14)	(0.0863)	(1.21)	(1.15)
Intangibles To Total Assets	0.0732	0.1	0.0281	0.0274	0.001363	0.001295
Net Debt To E B I T D A	0.39	0.89	0.41	0.53	0.34	0.32
Current Ratio	3.74	3.87	8.94	10.55	4.16	3.95
Tangible Book Value Per Share	1.52	0.72	3.35	2.92	2.25	4.19
Receivables Turnover	6.0	8.4	10.85	61.47	104.86	110.11
Graham Number	11.47	4.89	12.56	9.63	8.01	15.48
Shareholders Equity Per Share	1.69	0.89	3.48	3.03	2.25	2.14
Debt To Equity	0.009111	0.3	0.003512	0.003461	0.00271	0.002575
Capex Per Share	0.039	0.0106	0.005429	0.009277	0.0188	0.0331

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Aclaris Stock Analysis

When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Aclaris Historical Financial Ratios

About Aclaris Financial Ratios Analysis

Aclaris Therapeutics Financial Ratios Chart

Price To Sales Ratio

Ptb Ratio

Operating Cash Flow Per Share

Ev To Sales

Asset Turnover

Aclaris Therapeutics fundamentals Correlations

Aclaris Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Aclaris Therapeutics fundamentals Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Aclaris Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Pfcf Ratio	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 1.0	Pfcf Ratio

Capex To Operating Cash Flow	- 0.98	Capex To Depreciation
Pb Ratio	- 0.94	Capex To Depreciation
Capex To Depreciation	- 0.94	Ptb Ratio
Pe Ratio	- 0.87	Roic
Pe Ratio	- 0.87	Capex To Depreciation
Payables Turnover	- 0.87	Days Sales Outstanding